Clinical Trial Update: A Phase I Study of CFT8919 in Patients With Advanced NSCLC [Phase 1]

View source ↗

Summary

A Phase I clinical trial of CFT8919 in patients with advanced non-small cell lung cancer carrying EGFR mutations; the study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CFT8919

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Non-Small Cell Lung Cancer With EGFR Mutation | Phase 1 | Status: NOT_YET_RECRUITING